The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.
Abbvie stock is a good long-term buy and hold on a “dream-team” pipeline of phase 3 trials.
Amgen stock looks like a good setup as the Twiggs Money Flow breaks into positive territory.
BioLife Solutions stock has rising large players volume and a rising Twiggs Money Flow as revenue surges higher from the CAR T cell revolution.
Shire stock has rising large players volume and Twiggs Money Flow. The company just filed with the FDA for a new manufacturing facility in Georgia.
Allergan stock is a turnaround gambit on the stock being crushed over fears of a Botox competitor. Large players volume is rising and the Twiggs Money Flow just went positive.
Abbott Laboratories stock is uptrending in a continuation pattern. The company beat on earnings and revenue and has since consolidated.
Celgene stock has formed a great looking consolidation or basing pattern after dropping -35% on news that was not too bad. I think we have a great bottom feeder play here.
Sarepta Therapeutics could get European marketing approval for Exondys 51 at any time which will boost sales. Meanwhile, the company has great growth and is advancing other drugs through its pipeline.
Adamis Pharmaceuticals is looking at various licensing partners for its FDA approved Symjepi which will compete against Mylan’s EpiPen. As soon as the company announces a licensing partner, this stock could explode over 130 percent higher.
The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 14 2017”